================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 14, 2006
Immunomedics, Inc.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-12104 61-1009366
---------------------------- ------------ -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
300 American Road, Morris Plains, New Jersey 07950
-------------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
(973) 605-8200
(Registrant's telephone number, including area code)
Not applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425).
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12).
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)).
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)).
================================================================================
ITEM 8.01. OTHER EVENT.
On November 14, 2006, Immunomedics, Inc., a Delaware corporation (the
"Company"), issued a press release announcing that their partner, UCB, S.A., has
received notification from Food and Drug Administration that the clinical hold
on existing trials with epratuzumab in patients with lupus has been lifted.
The full text of the press release is attached to this current report on Form
8-K as Exhibit 99.1 hereto and is incorporated by reference herein.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
Exhibit No. Description
----------- ------------------------------------------------------------
99.1 Press Release of Immunomedics, Inc. dated November 14, 2006
announcing the lifting of clinical hold status by the FDA.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IMMUNOMEDICS, INC.
By: /s/ Cynthia L. Sullivan
-----------------------------
Name: Cynthia L. Sullivan
Title: President and Chief Executive
Officer
Date: November 15, 2006